The FINANCIAL — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today positive data for Olumiant® (baricitinib) will be presented at ACR Convergence 2020, the American College of Rheumatology’s virtual annual meeting taking place November 5-9, 2020. The Olumiant data being presented at this year’s meeting include new long-term studies in adult patients living with rheumatoid arthritis (RA), along with real-world evidence (RWE) on safety and efficacy. At this year’s meeting, results from a post-hoc analysis evaluating the long-term efficacy of Olumiant for patients with active RA who were inadequate responders (IR) to conventional synthetic disease-modifying antirheumatic drugs (csDMARD) or biologic DMARDs (bDMARD) (Abstract…
Read More »The FINANCIAL — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today positive data for Olumiant® (baricitinib) will be presented at ACR Convergence 2020, the American College of Rheumatology’s virtual annual meeting taking place November 5-9, 2020. The Olumiant data being presented at this year’s meeting include new long-term studies in adult patients living with rheumatoid arthritis (RA), along…
You might be interested in
It’s like we forgot how to drive, one Harvard expert observed recently about the two-year spike in traffic-related deaths, which…
SARS-CoV-2 infection can trigger the production of immune molecules that damage cells lining blood vessels in the brain, causing platelets…
The FINANCIAL — Researchers have found that around one in 500 men could be carrying an extra X or Y…
The FINANCIAL — COVID-19 was the third leading cause of death in the United States between March 2020 and October…